Focal segmental glomerulosclerosis (FSGS) is a pattern of kidney scarring that starts with damage to podocytes, the cells that keep protein out of the urine. About 5,000 Americans are diagnosed each year, and it is a leading cause of kidney failure in young people; causes include immune factors, genes (including APOL1 variants common in people of African ancestry) and other conditions. Steroids and other immunosuppressants help only some patients. In April 2026 sparsentan became the first drug approved for FSGS, and drugs that directly protect podocytes are now in phase 3.
- 31studies open or running
- 3phase 3 trials
- 333papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
The first FSGS approvalHappened 42.0% partial remission
Sparsentan raised partial remission of proteinuria vs irbesartan (42.0% vs 26.0%); FDA approved April 2026.
42.0%: partial remission of proteinuria at 36 weeks, vs 26.0%.
Protecting podocytes directlyHappened 35% proteinuria response
A TRPC6 blocker lowered proteinuria in 35% of patients vs 7% with placebo.
35%: proteinuria response across doses, vs 7% with placebo.
Finerenone adds protectionHappened 42% less albuminuria
In glomerular diseases including FSGS, finerenone cut albuminuria by 42% and slowed kidney function loss.
42%: reduction in albuminuria at 12 months.
-
6 months
by May 2027
Immune-targeted drugsPossible
Sanofi's trial of frexalimab, brivekimig and rilzabrutinib (84 people) finishes December 2026.
-
12 months
by Nov 2027
Sparsentan in practiceLikely
Uptake of the first approved drug, including in genetic FSGS, where immune drugs rarely work.
A podocyte antibodyPossible
Walden's WAL0921 (96 people) is due March 2027.
-
3 years
by late 2029
TRPC6 blocker phase 3Possible 35% proteinuria response (phase 2)
Boehringer's BI 764198 phase 3 (286 people) is due December 2028.
35%: proteinuria response across doses, vs 7% with placebo.
Treating childrenPossible
Sparsentan is being tested in children with protein-leaking kidney diseases.
-
5 years
by late 2031
Complement blockadeLong shot
Apellis' pegcetacoplan phase 2/3 (270 people) is due October 2029.
Treatment by causeLong shot
Anti-nephrin antibodies, APOL1 genotype and other markers may sort patients toward immune, genetic or podocyte-targeted treatment.
The research paths
Dual blockers and kidney protection
42.0% partial remissionDetails and 2 trialsHide
Sparsentan, finerenone and related drugs that reduce proteinuria.
WatchPediatric sparsentan.
Podocyte-targeted drugs
35% proteinuria responseDetails and 3 trialsHide
Drugs that protect the kidney filter cells directly.
WatchBI 764198 phase 3; WAL0921.
Immune and complement drugs
Details and 3 trialsHide
Antibodies against immune signals, complement blockers and B-cell drugs.
WatchSanofi trial; pegcetacoplan.
Borrowed from other conditions
From Diabetic kidney disease and heart failure
Finerenone
Phase 3 analysis
A mineralocorticoid receptor blocker approved for kidney disease with diabetes.
From PNH and geographic atrophy
Pegcetacoplan
Phase 2/3
A complement C3 blocker approved for a blood disease and an eye disease.
From Immune thrombocytopenia
Rilzabrutinib
Phase 2
A BTK inhibitor approved for ITP in 2025.
Open to join now
-
FSGS
BI 764198
Locations and eligibility → -
FSGS
Pegcetacoplan
Locations and eligibility → -
Primary FSGS
Frexalimab, brivekimig or rilzabrutinib
Locations and eligibility → -
FSGS
Praliciguat
Locations and eligibility →
See every recruiting FSGS trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
FDA approves sparsentan, first drug for FSGS
Based on DUPLEX.
TRPC6 blocker lowers proteinuria
The Lancet.
Standard treatment today
- All patientsBlood pressure control with ACE inhibitors or ARBs; sparsentan; SGLT2 inhibitors.
- Primary (immune) FSGSSteroids; calcineurin inhibitors or rituximab if steroids fail.
- Genetic FSGSKidney-protecting drugs; immunosuppression usually avoided.
- Kidney failureDialysis or transplant; FSGS can recur after transplant.
How to read this page, and sourcesHow to read this page, and sources
- FSGS has several causes; which treatment helps depends on whether it is immune, genetic or secondary to another condition.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See FSGS trials recruiting now →